Amadori and Heyns rearrangement products of bioactive peptides as potential new ligands of galectin-3

Non-enzymatic cascade reactions between amines and reducing sugars are known as Maillard reaction. The late phase of these reactions consists of advanced glycation end products (AGEs), which have been implicated in the pathogenesis of numerous human diseases. Recent evidence suggests that galectin-3...

Full description

Saved in:
Bibliographic Details
Published inCarbohydrate research Vol. 542; p. 109195
Main Authors Jakas, Andreja, Ayyalasomayajula, Ramya, Cudic, Mare
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 01.08.2024
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Non-enzymatic cascade reactions between amines and reducing sugars are known as Maillard reaction. The late phase of these reactions consists of advanced glycation end products (AGEs), which have been implicated in the pathogenesis of numerous human diseases. Recent evidence suggests that galectin-3 acts as a receptor for AGEs and some early products of the Maillard reaction. The early phase of the Maillard reaction, which consists of 1-amino-1-deoxyketoses (Amadori compounds) and 2-amino-2-deoxyaldoses (Heyns compounds), was the subject of our study. The binding interactions between galectin-3 and the Amadori and Heyns compounds of leucine-enkephalin (YGGFL), leucine-enkephalin methyl ester (YGGFL-OMe), truncated enkephalin (YGG and Y) and tetrapeptide (LSKL) were measured using the AlphaScreen competitive binding assay. The affinity of galectin-3 for Amadori and Heyns compounds depends on both the sugar moiety and the amino acid sequence of the model compounds. The best results were obtained with Leu-enkephalin derivatives of Amadori (IC50 = 6.06 μm) and Heyns (IC50 = 8.6 μm) compound, respectively. [Display omitted] •The interactions between Amadori and Heyns compounds of Leu-enkephalin and the tetrapeptide Leu-Ser-Lys-Leu with galectin-3 were investigated.•The AlphaScreen competitive binding assay was used to study the interactions of Amadori and Heyns compounds with galectin-3.•The Heyns compounds showed a higher affinity for galectin-3 compared to Amadori compounds.•The lack of the aromatic residues within the peptide sequence, showed a significantly lower affinity for galectin-3.
AbstractList Non-enzymatic cascade reactions between amines and reducing sugars are known as Maillard reaction. The late phase of these reactions consists of advanced glycation end products (AGEs), which have been implicated in the pathogenesis of numerous human diseases. Recent evidence suggests that galectin-3 acts as a receptor for AGEs and some early products of the Maillard reaction. The early phase of the Maillard reaction, which consists of 1-amino-1-deoxyketoses (Amadori compounds) and 2-amino-2-deoxyaldoses (Heyns compounds), was the subject of our study. The binding interactions between galectin-3 and the Amadori and Heyns compounds of leucine-enkephalin (YGGFL), leucine-enkephalin methyl ester (YGGFL-OMe), truncated enkephalin (YGG and Y) and tetrapeptide (LSKL) were measured using the AlphaScreen competitive binding assay. The affinity of galectin-3 for Amadori and Heyns compounds depends on both the sugar moiety and the amino acid sequence of the model compounds. The best results were obtained with Leu-enkephalin derivatives of Amadori (IC₅₀=6.06 μm) and Heyns (IC₅₀=8.6 μm) compound, respectively.
Non-enzymatic cascade reactions between amines and reducing sugars are known as Maillard reaction. The late phase of these reactions consists of advanced glycation end products (AGEs), which have been implicated in the pathogenesis of numerous human diseases. Recent evidence suggests that galectin-3 acts as a receptor for AGEs and some early products of the Maillard reaction. The early phase of the Maillard reaction, which consists of 1-amino-1-deoxyketoses (Amadori compounds) and 2-amino-2-deoxyaldoses (Heyns compounds), was the subject of our study. The binding interactions between galectin-3 and the Amadori and Heyns compounds of leucine-enkephalin (YGGFL), leucine-enkephalin methyl ester (YGGFL-OMe), truncated enkephalin (YGG and Y) and tetrapeptide (LSKL) were measured using the AlphaScreen competitive binding assay. The affinity of galectin-3 for Amadori and Heyns compounds depends on both the sugar moiety and the amino acid sequence of the model compounds. The best results were obtained with Leu-enkephalin derivatives of Amadori (IC50 = 6.06 μm) and Heyns (IC50 = 8.6 μm) compound, respectively. [Display omitted] •The interactions between Amadori and Heyns compounds of Leu-enkephalin and the tetrapeptide Leu-Ser-Lys-Leu with galectin-3 were investigated.•The AlphaScreen competitive binding assay was used to study the interactions of Amadori and Heyns compounds with galectin-3.•The Heyns compounds showed a higher affinity for galectin-3 compared to Amadori compounds.•The lack of the aromatic residues within the peptide sequence, showed a significantly lower affinity for galectin-3.
Non-enzymatic cascade reactions between amines and reducing sugars are known as Maillard reaction. The late phase of these reactions consists of advanced glycation end products (AGEs), which have been implicated in the pathogenesis of numerous human diseases. Recent evidence suggests that galectin-3 acts as a receptor for AGEs and some early products of the Maillard reaction. The early phase of the Maillard reaction, which consists of 1-amino-1-deoxyketoses (Amadori compounds) and 2-amino-2-deoxyaldoses (Heyns compounds), was the subject of our study. The binding interactions between galectin-3 and the Amadori and Heyns compounds of leucine-enkephalin (YGGFL), leucine-enkephalin methyl ester (YGGFL-OMe), truncated enkephalin (YGG and Y) and tetrapeptide (LSKL) were measured using the AlphaScreen competitive binding assay. The affinity of galectin-3 for Amadori and Heyns compounds depends on both the sugar moiety and the amino acid sequence of the model compounds. The best results were obtained with Leu-enkephalin derivatives of Amadori (IC  = 6.06 μm) and Heyns (IC  = 8.6 μm) compound, respectively.
Non-enzymatic cascade reactions between amines and reducing sugars are known as Maillard reaction. The late phase of these reactions consists of advanced glycation end products (AGEs), which have been implicated in the pathogenesis of numerous human diseases. Recent evidence suggests that galectin-3 acts as a receptor for AGEs and some early products of the Maillard reaction. The early phase of the Maillard reaction, which consists of 1-amino-1-deoxyketoses (Amadori compounds) and 2-amino-2-deoxyaldoses (Heyns compounds), was the subject of our study. The binding interactions between galectin-3 and the Amadori and Heyns compounds of leucine-enkephalin (YGGFL), leucine-enkephalin methyl ester (YGGFL-OMe), truncated enkephalin (YGG and Y) and tetrapeptide (LSKL) were measured using the AlphaScreen competitive binding assay. The affinity of galectin-3 for Amadori and Heyns compounds depends on both the sugar moiety and the amino acid sequence of the model compounds. The best results were obtained with Leu-enkephalin derivatives of Amadori (IC50 = 6.06 μm) and Heyns (IC50 = 8.6 μm) compound, respectively.Non-enzymatic cascade reactions between amines and reducing sugars are known as Maillard reaction. The late phase of these reactions consists of advanced glycation end products (AGEs), which have been implicated in the pathogenesis of numerous human diseases. Recent evidence suggests that galectin-3 acts as a receptor for AGEs and some early products of the Maillard reaction. The early phase of the Maillard reaction, which consists of 1-amino-1-deoxyketoses (Amadori compounds) and 2-amino-2-deoxyaldoses (Heyns compounds), was the subject of our study. The binding interactions between galectin-3 and the Amadori and Heyns compounds of leucine-enkephalin (YGGFL), leucine-enkephalin methyl ester (YGGFL-OMe), truncated enkephalin (YGG and Y) and tetrapeptide (LSKL) were measured using the AlphaScreen competitive binding assay. The affinity of galectin-3 for Amadori and Heyns compounds depends on both the sugar moiety and the amino acid sequence of the model compounds. The best results were obtained with Leu-enkephalin derivatives of Amadori (IC50 = 6.06 μm) and Heyns (IC50 = 8.6 μm) compound, respectively.
ArticleNumber 109195
Author Cudic, Mare
Ayyalasomayajula, Ramya
Jakas, Andreja
Author_xml – sequence: 1
  givenname: Andreja
  orcidid: 0000-0001-6095-7515
  surname: Jakas
  fullname: Jakas, Andreja
  email: Andreja.Jakas@irb.hr
  organization: Rudjer Bošković Institute, Division of Organic Chemistry and Biochemistry, Bijenička c. 54, 10000, Zagreb, Croatia
– sequence: 2
  givenname: Ramya
  orcidid: 0000-0002-7610-0097
  surname: Ayyalasomayajula
  fullname: Ayyalasomayajula, Ramya
  organization: Florida Atlantic University, Department of Chemistry and Biochemistry, 777 Glades Rd., Boca Raton, FL, 33431, USA
– sequence: 3
  givenname: Mare
  surname: Cudic
  fullname: Cudic, Mare
  email: mcudic@fau.edu
  organization: Florida Atlantic University, Department of Chemistry and Biochemistry, 777 Glades Rd., Boca Raton, FL, 33431, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38908217$$D View this record in MEDLINE/PubMed
BookMark eNqFkU9rFTEUxYNU7Gv1G4hk6WZe82-SjAuhFLWFghsFdyEvufPIYyYZk7yWfntTp924sKtww-8c7j3nDJ3EFAGh95RsKaHy4rB1NmcoW0aYaF8DHfpXaEO14p1g8tcJ2hBCdCcZ7U_RWSmHNhKp5Bt0yvVANKNqg-Bytj7lgG30-BoeYsEZmq-Ne5ghVrzk5I-uFpxGvAvJuhruAC-w1OChYFvwkmoDg51whHs8hX2z-ovv7QQNjx1_i16Pdirw7uk9Rz-_fvlxdd3dfv92c3V52zk-9LUbueKSSS00tVRyRiQfJR846XvihdaghB6d970iSu9Ail5IxdoxwEDzgfFz9HH1bVv_PkKpZg7FwTTZCOlYDKc9l1IMRL2MEkWZ5pzShn54Qo-7GbxZcphtfjDPKTbg0wq4nErJMBoXqq0hxZptmAwl5rEyczBrZeaxMrNW1sTiH_Gz_wuyz6sMWp53AbIpLkB04ENuqRufwv8N_gBfpbAT
CitedBy_id crossref_primary_10_3390_molecules30020226
Cites_doi 10.1039/P29960000789
10.1155/2012/894605
10.1021/bi051144z
10.3390/cells10113047
10.1080/14728222.2019.1675638
10.1074/jbc.M109.098160
10.1046/j.1523-1755.2000.07706.x
10.1016/S0304-4165(97)00086-X
10.1002/psc.1029
10.1021/acsmedchemlett.9b00540
10.1016/j.str.2010.05.017
10.1016/j.carres.2008.07.003
10.1056/NEJMsb1503104
10.1002/bip.10338
10.1002/psc.519
10.1021/acs.jmedchem.7b00058
10.1093/glycob/cwj056
10.1093/glycob/cwu111
10.3390/nu9080835
10.1007/s10719-020-09951-x
10.1016/j.ab.2013.04.028
10.1023/B:GLYC.0000014072.34840.04
10.1016/j.ccell.2019.06.006
10.1093/glycob/cwv073
10.1007/BF00053899
10.1152/ajpcell.00089.2020
10.1186/s12014-017-9146-0
10.1158/0008-5472.CAN-07-3233
10.1096/fj.04-2031fje
10.1007/BF03401604
10.1021/acs.biochem.5b00555
10.1002/rcm.7775
ContentType Journal Article
Copyright 2024 Elsevier Ltd
Copyright © 2024 Elsevier Ltd. All rights reserved.
Copyright_xml – notice: 2024 Elsevier Ltd
– notice: Copyright © 2024 Elsevier Ltd. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7S9
L.6
DOI 10.1016/j.carres.2024.109195
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList AGRICOLA

MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
EISSN 1873-426X
ExternalDocumentID 38908217
10_1016_j_carres_2024_109195
S0008621524001745
Genre Journal Article
GroupedDBID ---
--K
--M
-~X
.55
.GJ
.~1
0R~
1B1
1RT
1~.
1~5
29B
4.4
457
4G.
53G
5GY
5VS
7-5
71M
8P~
9JM
9JN
AABNK
AACTN
AAEDT
AAEDW
AAHBH
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AARLI
AAXUO
ABFNM
ABGSF
ABJNI
ABMAC
ABUDA
ABXDB
ACDAQ
ACGFS
ACNCT
ACNNM
ACRLP
ADBBV
ADECG
ADEZE
ADMUD
ADUVX
AEBSH
AEHWI
AEKER
AENEX
AFFNX
AFKWA
AFTJW
AFXIZ
AFZHZ
AGHFR
AGRDE
AGUBO
AGYEJ
AHHHB
AIEXJ
AIKHN
AITUG
AJOXV
AJSZI
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
CS3
DU5
EBS
EFJIC
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FLBIZ
FNPLU
FYGXN
G-Q
GBLVA
HMS
HVGLF
HZ~
H~9
IHE
J1W
KOM
M2Z
M41
MO0
MVM
N9A
O-L
O9-
OAUVE
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
RNS
ROL
RPZ
SCB
SDF
SDG
SDP
SES
SEW
SOC
SPC
SPCBC
SSK
SSU
SSZ
T5K
WUQ
X7M
XPP
Y6R
YK3
ZXP
~02
~G-
~KM
AATTM
AAXKI
AAYWO
AAYXX
ABWVN
ACRPL
ACVFH
ADCNI
ADNMO
AEIPS
AEUPX
AFJKZ
AFPUW
AGCQF
AGQPQ
AGRNS
AIGII
AIIUN
AKBMS
AKYEP
ANKPU
APXCP
BNPGV
CITATION
SSH
CGR
CUY
CVF
ECM
EFKBS
EIF
NPM
7X8
7S9
L.6
ID FETCH-LOGICAL-c395t-f3736268481a1632063f63930550d488e748fcdd57078be6454672389e2e83923
IEDL.DBID .~1
ISSN 0008-6215
1873-426X
IngestDate Wed May 21 16:29:23 EDT 2025
Mon Jul 21 11:21:05 EDT 2025
Mon Jul 21 06:06:47 EDT 2025
Tue Jul 01 04:05:13 EDT 2025
Thu Apr 24 23:11:04 EDT 2025
Sat Jul 20 16:36:03 EDT 2024
IsPeerReviewed true
IsScholarly true
Keywords Maillard reaction
Amadori compounds
Galectin-3
Leu-enkephalin
AlphaScreen
Heyns compounds
Language English
License Copyright © 2024 Elsevier Ltd. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c395t-f3736268481a1632063f63930550d488e748fcdd57078be6454672389e2e83923
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-6095-7515
0000-0002-7610-0097
PMID 38908217
PQID 3071283311
PQPubID 23479
ParticipantIDs proquest_miscellaneous_3153664907
proquest_miscellaneous_3071283311
pubmed_primary_38908217
crossref_citationtrail_10_1016_j_carres_2024_109195
crossref_primary_10_1016_j_carres_2024_109195
elsevier_sciencedirect_doi_10_1016_j_carres_2024_109195
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-08-01
PublicationDateYYYYMMDD 2024-08-01
PublicationDate_xml – month: 08
  year: 2024
  text: 2024-08-01
  day: 01
PublicationDecade 2020
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Carbohydrate research
PublicationTitleAlternate Carbohydr Res
PublicationYear 2024
Publisher Elsevier Ltd
Publisher_xml – name: Elsevier Ltd
References Teodorowicz, Van Neerven, Savelkoul (bib13) 2017; 9
Koch, Chitayat, Dattilo, Schiefner, Diez, Chazin, Fritz (bib6) 2010; 18
FitzGerald, Rodriguez Benavente, Garcia, Rivero, Singh, Wang, Fields, Cudic (bib35) 2020; 37
Iacobini, Menini, Oddi, Ricci, Amadio, Pricci, Olivieri, Sorcini, Di Mario, Pesce, Pugliese (bib21) 2004; 18
Chuah, Basir, Talib, Tie, Nordin (bib10) 2013; 2013
Nangia-Makker, Raz, Tait, Hogan, Fridman, Raz (bib18) 2007; 67
Pricci, Leto, Amadio, Iacobini, Romeo, Cordone, Gradini, Barsotti, Liu, Di Mario, Pugliese (bib24) 2000; 58
Soares, Al-Dalahmah, Hillis, Young, Asbed, Sakaguchi, O'Neill, Szele (bib29) 2021; 10
Buckle, Forbes (bib7) 2023
Pugliese, Iacobini, Pesce, Menini (bib20) 2015; 25
Suto, Gupta, Mathew, Zhang, Pallero, Murphy-Ullrich (bib31) 2020; 11
Horvat, Jakas (bib1) 2004; 10
Jovanović, Peter‐Katalinić (bib11) 2017; 31
Isenberg, Roberts (bib30) 2020; 319
Glinsky, Mossine, Price, Bielenberg, Glinsky, Ananthaswamy, Feather (bib32) 1996; 14
Jakas, Katić, Bionda, Horvat (bib4) 2008; 343
Ochieng (bib19) 1998; 1379
Leffler, Carlsson, Hedlund, Qian, Poirier (bib16) 2002; 19
Mereiter, Balmaña, Campos, Gomes, Reis (bib26) 2019; 36
Rodriguez, Yegorova, Pitteloud, Chavaroche, André, Ardá, Minond, Jiménez-Barbero, Gabius, Cudic (bib34) 2015; 54
Cullen, Cascella (bib27) 2024 Jan
Win, Yamamoto, Munesue, Saito, Han, Motoyoshi, Kamal, Ohara, Watanabe, Yamamoto (bib9) 2012; 2012
Vlassara, Li, Imani, Wojciechowicz, Yang, Liu, Cerami (bib12) 1995; 1
Ho, Springer (bib17) 1982; 128
Miller, Ippel, Suylen, Klyosov, Traber, Hackeng, Mayo (bib36) 2016; 26
Romero, Gabius (bib15) 2019; 23
Jakas, Horvat (bib3) 1996; 2
Bongarzone, Savickas, Luzi, Gee (bib8) 2017; 60
Nielsen, Østergaard, Rasmussen, Jacobsen, Heegaard (bib22) 2017; 14
Yegorova, Chavaroche, Rodriguez, Minond, Cudic (bib33) 2013; 439
Salomonsson, Carlsson, Osla, Hendus-Altenburger, Kahl-Knutson, Öberg, Sundin, Nilsson, Nordberg-Karlsson, Nilsson, Karlsson, Rini, Leffler (bib37) 2010; 285
Jakas, Horvat (bib2) 2003; 69
Jakas, Vinković, Smrečki, Šporec, Horvat (bib5) 2008; 14
Jameson, Longo (bib25) 2015; 372
Khawaja, Green, Thorpe, Titheradge (bib28) 1990; 267
Rabinovich, Cumashi, Bianco, Ciavardelli, Iurisci, D'Egidio, Piccolo, Tinari, Nifantiev, Iacobelli (bib14) 2006; 16
Dam, Gabius, André, Kaltner, Lensch, Brewer (bib23) 2005; 44
Iacobini (10.1016/j.carres.2024.109195_bib21) 2004; 18
Horvat (10.1016/j.carres.2024.109195_bib1) 2004; 10
Nangia-Makker (10.1016/j.carres.2024.109195_bib18) 2007; 67
Yegorova (10.1016/j.carres.2024.109195_bib33) 2013; 439
Jakas (10.1016/j.carres.2024.109195_bib2) 2003; 69
Rodriguez (10.1016/j.carres.2024.109195_bib34) 2015; 54
Glinsky (10.1016/j.carres.2024.109195_bib32) 1996; 14
FitzGerald (10.1016/j.carres.2024.109195_bib35) 2020; 37
Miller (10.1016/j.carres.2024.109195_bib36) 2016; 26
Teodorowicz (10.1016/j.carres.2024.109195_bib13) 2017; 9
Suto (10.1016/j.carres.2024.109195_bib31) 2020; 11
Pugliese (10.1016/j.carres.2024.109195_bib20) 2015; 25
Jakas (10.1016/j.carres.2024.109195_bib4) 2008; 343
Soares (10.1016/j.carres.2024.109195_bib29) 2021; 10
Jakas (10.1016/j.carres.2024.109195_bib3) 1996; 2
Buckle (10.1016/j.carres.2024.109195_bib7) 2023
Rabinovich (10.1016/j.carres.2024.109195_bib14) 2006; 16
Mereiter (10.1016/j.carres.2024.109195_bib26) 2019; 36
Isenberg (10.1016/j.carres.2024.109195_bib30) 2020; 319
Jameson (10.1016/j.carres.2024.109195_bib25) 2015; 372
Vlassara (10.1016/j.carres.2024.109195_bib12) 1995; 1
Ochieng (10.1016/j.carres.2024.109195_bib19) 1998; 1379
Romero (10.1016/j.carres.2024.109195_bib15) 2019; 23
Salomonsson (10.1016/j.carres.2024.109195_bib37) 2010; 285
Koch (10.1016/j.carres.2024.109195_bib6) 2010; 18
Khawaja (10.1016/j.carres.2024.109195_bib28) 1990; 267
Leffler (10.1016/j.carres.2024.109195_bib16) 2002; 19
Nielsen (10.1016/j.carres.2024.109195_bib22) 2017; 14
Jovanović (10.1016/j.carres.2024.109195_bib11) 2017; 31
Ho (10.1016/j.carres.2024.109195_bib17) 1982; 128
Chuah (10.1016/j.carres.2024.109195_bib10) 2013; 2013
Bongarzone (10.1016/j.carres.2024.109195_bib8) 2017; 60
Jakas (10.1016/j.carres.2024.109195_bib5) 2008; 14
Pricci (10.1016/j.carres.2024.109195_bib24) 2000; 58
Dam (10.1016/j.carres.2024.109195_bib23) 2005; 44
Win (10.1016/j.carres.2024.109195_bib9) 2012; 2012
Cullen (10.1016/j.carres.2024.109195_bib27) 2024
References_xml – volume: 9
  start-page: 835
  year: 2017
  ident: bib13
  article-title: Food processing: the influence of the maillard reaction on immunogenicity and allergenicity of food proteins
  publication-title: Nutrients
– volume: 372
  start-page: 2229
  year: 2015
  end-page: 2234
  ident: bib25
  article-title: Precision medicine — personalized, problematic, and promising
  publication-title: N. Engl. J. Med.
– volume: 319
  start-page: C45
  year: 2020
  end-page: C63
  ident: bib30
  article-title: Thrombospondin-1 in maladaptive aging responses: a concept whose time has come
  publication-title: Am. J. Physiol.-Cell Physiol.
– volume: 2013
  start-page: 1
  year: 2013
  end-page: 15
  ident: bib10
  article-title: Receptor for advanced glycation end products and its involvement in inflammatory diseases
  publication-title: Intern. J Inflam
– volume: 37
  start-page: 657
  year: 2020
  end-page: 666
  ident: bib35
  article-title: TF-containing MUC1 glycopeptides fail to entice Galectin-1 recognition of tumor-associated Thomsen-Freidenreich (TF) antigen (CD176) in solution
  publication-title: Glycoconj. J.
– volume: 1
  start-page: 634
  year: 1995
  end-page: 646
  ident: bib12
  article-title: Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex
  publication-title: Mol. Med.
– start-page: 1
  year: 2023
  end-page: 15
  ident: bib7
  article-title: The role of the receptor for advanced glycation endproducts (RAGE) in type 1 diabetes: an immune cell perspective
  publication-title: Type 1 Diabetes 2023 - Real Pract
– volume: 18
  start-page: 1773
  year: 2004
  end-page: 1775
  ident: bib21
  article-title: Galectin‐3/AGE‐receptor 3 knockout mice show accelerated AGE‐induced glomerular injury: evidence for a protective role of galectin‐3 as an AGE receptor
  publication-title: FASEB J
– volume: 26
  start-page: 88
  year: 2016
  end-page: 99
  ident: bib36
  article-title: Binding of polysaccharides to human galectin-3 at a noncanonical site in its carbohydrate recognition domain
  publication-title: Glycobiology
– year: 2024 Jan
  ident: bib27
  article-title: Physiology, Enkephalin
  publication-title: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing
– volume: 44
  start-page: 12564
  year: 2005
  end-page: 12571
  ident: bib23
  article-title: Galectins bind to the multivalent glycoprotein asialofetuin with enhanced affinities and a gradient of decreasing binding constants
  publication-title: Biochemistry
– volume: 60
  start-page: 7213
  year: 2017
  end-page: 7232
  ident: bib8
  article-title: Targeting the receptor for advanced glycation endproducts (RAGE): a medicinal chemistry perspective
  publication-title: J. Med. Chem.
– volume: 14
  start-page: 253
  year: 1996
  end-page: 267
  ident: bib32
  article-title: Inhibition of colony formation in agarose of metastatic human breast carcinoma and melanoma cells by synthetic glycoamine analogs
  publication-title: Clin. Exp. Metastasis
– volume: 439
  start-page: 123
  year: 2013
  end-page: 131
  ident: bib33
  article-title: Development of an AlphaScreen assay for discovery of inhibitors of low-affinity glycan–lectin interactions
  publication-title: Anal. Biochem.
– volume: 2
  start-page: 789
  year: 1996
  end-page: 794
  ident: bib3
  article-title: Synthesis and
  publication-title: J Chem Soc Perkin Trans
– volume: 14
  start-page: 936
  year: 2008
  end-page: 945
  ident: bib5
  article-title: Fructose‐induced
  publication-title: J Pep Sci
– volume: 343
  start-page: 2475
  year: 2008
  end-page: 2480
  ident: bib4
  article-title: Glycation of a lysine-containing tetrapeptide by d-glucose and d-fructose—influence of different reaction conditions on the formation of Amadori/Heyns products
  publication-title: Carbohydr. Res.
– volume: 23
  start-page: 819
  year: 2019
  end-page: 828
  ident: bib15
  article-title: Galectin-3: is this member of a large family of multifunctional lectins (already) a therapeutic target?
  publication-title: Expert Opin. Ther. Targets
– volume: 67
  start-page: 11760
  year: 2007
  end-page: 11768
  ident: bib18
  article-title: Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers
  publication-title: Cancer Res.
– volume: 36
  start-page: 6
  year: 2019
  end-page: 16
  ident: bib26
  article-title: Glycosylation in the era of cancer-targeted therapy: where are we heading?
  publication-title: Cancer Cell
– volume: 19
  start-page: 433
  year: 2002
  end-page: 440
  ident: bib16
  article-title: Introduction to galectins
  publication-title: Glycoconj. J.
– volume: 128
  start-page: 1221
  year: 1982
  end-page: 1228
  ident: bib17
  article-title: Mac-2, a novel 32,000 Mr mouse macrophage subpopulation-specific antigen defined by monoclonal antibodies
  publication-title: J. Immunol. Baltim. Md 1950
– volume: 58
  start-page: S31
  year: 2000
  end-page: S39
  ident: bib24
  article-title: Role of galectin-3 as a receptor for advanced glycosylation end products
  publication-title: Kidney Int.
– volume: 285
  start-page: 35079
  year: 2010
  end-page: 35091
  ident: bib37
  article-title: Mutational tuning of galectin-3 specificity and biological function
  publication-title: J. Biol. Chem.
– volume: 25
  start-page: 136
  year: 2015
  end-page: 150
  ident: bib20
  article-title: Galectin-3: an emerging all-out player in metabolic disorders and their complications
  publication-title: Glycobiology
– volume: 14
  start-page: 11
  year: 2017
  ident: bib22
  article-title: A review of studies of the proteomes of circulating microparticles: key roles for galectin-3-binding protein-expressing microparticles in vascular diseases and systemic lupus erythematosus
  publication-title: Clin. Proteomics
– volume: 54
  start-page: 4462
  year: 2015
  end-page: 4474
  ident: bib34
  article-title: Thermodynamic switch in binding of adhesion/growth regulatory human galectin-3 to tumor-associated TF antigen (CD176) and MUC1 glycopeptides
  publication-title: Biochemistry
– volume: 267
  start-page: 233
  year: 1990
  end-page: 240
  ident: bib28
  article-title: The occurrence and receptor specificity of endogenous opioid peptides within the pancreas and liver of the rat
  publication-title: Comparison with brain, Biochem. J.
– volume: 69
  start-page: 421
  year: 2003
  end-page: 431
  ident: bib2
  article-title: Study of degradation pathways of Amadori compounds obtained by glycation of opioid pentapeptide and related smaller fragments: stability, reactions, and spectroscopic properties
  publication-title: Biopolymers
– volume: 16
  start-page: 210
  year: 2006
  end-page: 220
  ident: bib14
  article-title: Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis
  publication-title: Glycobiology
– volume: 10
  start-page: 3047
  year: 2021
  ident: bib29
  article-title: Novel galectin-3 roles in neurogenesis, inflammation and neurological diseases
  publication-title: Cells
– volume: 1379
  start-page: 97
  year: 1998
  end-page: 106
  ident: bib19
  article-title: Modulation of the biological functions of galectin-3 by matrix metalloproteinases
  publication-title: Biochim. Biophys. Acta BBA - Gen. Subj.
– volume: 18
  start-page: 1342
  year: 2010
  end-page: 1352
  ident: bib6
  article-title: Structural Basis for ligand recognition and activation of RAGE
  publication-title: Structure
– volume: 2012
  start-page: 1
  year: 2012
  end-page: 8
  ident: bib9
  article-title: Regulation of RAGE for attenuating progression of diabetic vascular complications, Exp
  publication-title: Diabetes Res.
– volume: 10
  start-page: 119
  year: 2004
  end-page: 137
  ident: bib1
  article-title: Peptide and amino acid glycation: new insights into the Maillard reaction
  publication-title: J. Pept. Sci.
– volume: 11
  start-page: 1130
  year: 2020
  end-page: 1136
  ident: bib31
  article-title: Identification of inhibitors of thrombospondin 1 activation of TGF-β
  publication-title: ACS Med. Chem. Lett.
– volume: 31
  start-page: 129
  year: 2017
  end-page: 136
  ident: bib11
  article-title: Preliminary mass spectrometry characterization studies of galectin‐3 samples, prior to carbohydrate‐binding studies using Affinity mass spectrometry
  publication-title: Rapid Commun. Mass Spectrom.
– volume: 2
  start-page: 789
  year: 1996
  ident: 10.1016/j.carres.2024.109195_bib3
  article-title: Synthesis and 13 C NMR investigation of novel Amadori compounds (1-amino-1-deoxy- D -fructose derivatives) related to the opioid peptide, leucine–enkephalin
  publication-title: J Chem Soc Perkin Trans
  doi: 10.1039/P29960000789
– volume: 2012
  start-page: 1
  year: 2012
  ident: 10.1016/j.carres.2024.109195_bib9
  article-title: Regulation of RAGE for attenuating progression of diabetic vascular complications, Exp
  publication-title: Diabetes Res.
  doi: 10.1155/2012/894605
– volume: 44
  start-page: 12564
  year: 2005
  ident: 10.1016/j.carres.2024.109195_bib23
  article-title: Galectins bind to the multivalent glycoprotein asialofetuin with enhanced affinities and a gradient of decreasing binding constants
  publication-title: Biochemistry
  doi: 10.1021/bi051144z
– volume: 10
  start-page: 3047
  year: 2021
  ident: 10.1016/j.carres.2024.109195_bib29
  article-title: Novel galectin-3 roles in neurogenesis, inflammation and neurological diseases
  publication-title: Cells
  doi: 10.3390/cells10113047
– volume: 23
  start-page: 819
  year: 2019
  ident: 10.1016/j.carres.2024.109195_bib15
  article-title: Galectin-3: is this member of a large family of multifunctional lectins (already) a therapeutic target?
  publication-title: Expert Opin. Ther. Targets
  doi: 10.1080/14728222.2019.1675638
– volume: 285
  start-page: 35079
  year: 2010
  ident: 10.1016/j.carres.2024.109195_bib37
  article-title: Mutational tuning of galectin-3 specificity and biological function
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M109.098160
– volume: 128
  start-page: 1221
  year: 1982
  ident: 10.1016/j.carres.2024.109195_bib17
  article-title: Mac-2, a novel 32,000 Mr mouse macrophage subpopulation-specific antigen defined by monoclonal antibodies
  publication-title: J. Immunol. Baltim. Md 1950
– volume: 58
  start-page: S31
  year: 2000
  ident: 10.1016/j.carres.2024.109195_bib24
  article-title: Role of galectin-3 as a receptor for advanced glycosylation end products
  publication-title: Kidney Int.
  doi: 10.1046/j.1523-1755.2000.07706.x
– year: 2024
  ident: 10.1016/j.carres.2024.109195_bib27
  article-title: Physiology, Enkephalin
– volume: 1379
  start-page: 97
  year: 1998
  ident: 10.1016/j.carres.2024.109195_bib19
  article-title: Modulation of the biological functions of galectin-3 by matrix metalloproteinases
  publication-title: Biochim. Biophys. Acta BBA - Gen. Subj.
  doi: 10.1016/S0304-4165(97)00086-X
– volume: 14
  start-page: 936
  year: 2008
  ident: 10.1016/j.carres.2024.109195_bib5
  article-title: Fructose‐induced N ‐terminal glycation of enkephalins and related peptides
  publication-title: J Pep Sci
  doi: 10.1002/psc.1029
– volume: 11
  start-page: 1130
  year: 2020
  ident: 10.1016/j.carres.2024.109195_bib31
  article-title: Identification of inhibitors of thrombospondin 1 activation of TGF-β
  publication-title: ACS Med. Chem. Lett.
  doi: 10.1021/acsmedchemlett.9b00540
– volume: 18
  start-page: 1342
  year: 2010
  ident: 10.1016/j.carres.2024.109195_bib6
  article-title: Structural Basis for ligand recognition and activation of RAGE
  publication-title: Structure
  doi: 10.1016/j.str.2010.05.017
– volume: 267
  start-page: 233
  year: 1990
  ident: 10.1016/j.carres.2024.109195_bib28
  article-title: The occurrence and receptor specificity of endogenous opioid peptides within the pancreas and liver of the rat
  publication-title: Comparison with brain, Biochem. J.
– volume: 343
  start-page: 2475
  year: 2008
  ident: 10.1016/j.carres.2024.109195_bib4
  article-title: Glycation of a lysine-containing tetrapeptide by d-glucose and d-fructose—influence of different reaction conditions on the formation of Amadori/Heyns products
  publication-title: Carbohydr. Res.
  doi: 10.1016/j.carres.2008.07.003
– volume: 372
  start-page: 2229
  year: 2015
  ident: 10.1016/j.carres.2024.109195_bib25
  article-title: Precision medicine — personalized, problematic, and promising
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMsb1503104
– volume: 69
  start-page: 421
  year: 2003
  ident: 10.1016/j.carres.2024.109195_bib2
  article-title: Study of degradation pathways of Amadori compounds obtained by glycation of opioid pentapeptide and related smaller fragments: stability, reactions, and spectroscopic properties
  publication-title: Biopolymers
  doi: 10.1002/bip.10338
– volume: 10
  start-page: 119
  year: 2004
  ident: 10.1016/j.carres.2024.109195_bib1
  article-title: Peptide and amino acid glycation: new insights into the Maillard reaction
  publication-title: J. Pept. Sci.
  doi: 10.1002/psc.519
– volume: 60
  start-page: 7213
  year: 2017
  ident: 10.1016/j.carres.2024.109195_bib8
  article-title: Targeting the receptor for advanced glycation endproducts (RAGE): a medicinal chemistry perspective
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.7b00058
– volume: 16
  start-page: 210
  year: 2006
  ident: 10.1016/j.carres.2024.109195_bib14
  article-title: Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis
  publication-title: Glycobiology
  doi: 10.1093/glycob/cwj056
– volume: 25
  start-page: 136
  year: 2015
  ident: 10.1016/j.carres.2024.109195_bib20
  article-title: Galectin-3: an emerging all-out player in metabolic disorders and their complications
  publication-title: Glycobiology
  doi: 10.1093/glycob/cwu111
– volume: 9
  start-page: 835
  year: 2017
  ident: 10.1016/j.carres.2024.109195_bib13
  article-title: Food processing: the influence of the maillard reaction on immunogenicity and allergenicity of food proteins
  publication-title: Nutrients
  doi: 10.3390/nu9080835
– volume: 37
  start-page: 657
  year: 2020
  ident: 10.1016/j.carres.2024.109195_bib35
  article-title: TF-containing MUC1 glycopeptides fail to entice Galectin-1 recognition of tumor-associated Thomsen-Freidenreich (TF) antigen (CD176) in solution
  publication-title: Glycoconj. J.
  doi: 10.1007/s10719-020-09951-x
– volume: 2013
  start-page: 1
  year: 2013
  ident: 10.1016/j.carres.2024.109195_bib10
  article-title: Receptor for advanced glycation end products and its involvement in inflammatory diseases
  publication-title: Intern. J Inflam
– volume: 439
  start-page: 123
  year: 2013
  ident: 10.1016/j.carres.2024.109195_bib33
  article-title: Development of an AlphaScreen assay for discovery of inhibitors of low-affinity glycan–lectin interactions
  publication-title: Anal. Biochem.
  doi: 10.1016/j.ab.2013.04.028
– volume: 19
  start-page: 433
  year: 2002
  ident: 10.1016/j.carres.2024.109195_bib16
  article-title: Introduction to galectins
  publication-title: Glycoconj. J.
  doi: 10.1023/B:GLYC.0000014072.34840.04
– volume: 36
  start-page: 6
  year: 2019
  ident: 10.1016/j.carres.2024.109195_bib26
  article-title: Glycosylation in the era of cancer-targeted therapy: where are we heading?
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2019.06.006
– volume: 26
  start-page: 88
  year: 2016
  ident: 10.1016/j.carres.2024.109195_bib36
  article-title: Binding of polysaccharides to human galectin-3 at a noncanonical site in its carbohydrate recognition domain
  publication-title: Glycobiology
  doi: 10.1093/glycob/cwv073
– volume: 14
  start-page: 253
  year: 1996
  ident: 10.1016/j.carres.2024.109195_bib32
  article-title: Inhibition of colony formation in agarose of metastatic human breast carcinoma and melanoma cells by synthetic glycoamine analogs
  publication-title: Clin. Exp. Metastasis
  doi: 10.1007/BF00053899
– volume: 319
  start-page: C45
  year: 2020
  ident: 10.1016/j.carres.2024.109195_bib30
  article-title: Thrombospondin-1 in maladaptive aging responses: a concept whose time has come
  publication-title: Am. J. Physiol.-Cell Physiol.
  doi: 10.1152/ajpcell.00089.2020
– volume: 14
  start-page: 11
  year: 2017
  ident: 10.1016/j.carres.2024.109195_bib22
  article-title: A review of studies of the proteomes of circulating microparticles: key roles for galectin-3-binding protein-expressing microparticles in vascular diseases and systemic lupus erythematosus
  publication-title: Clin. Proteomics
  doi: 10.1186/s12014-017-9146-0
– volume: 67
  start-page: 11760
  year: 2007
  ident: 10.1016/j.carres.2024.109195_bib18
  article-title: Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-07-3233
– start-page: 1
  year: 2023
  ident: 10.1016/j.carres.2024.109195_bib7
  article-title: The role of the receptor for advanced glycation endproducts (RAGE) in type 1 diabetes: an immune cell perspective
– volume: 18
  start-page: 1773
  year: 2004
  ident: 10.1016/j.carres.2024.109195_bib21
  article-title: Galectin‐3/AGE‐receptor 3 knockout mice show accelerated AGE‐induced glomerular injury: evidence for a protective role of galectin‐3 as an AGE receptor
  publication-title: FASEB J
  doi: 10.1096/fj.04-2031fje
– volume: 1
  start-page: 634
  year: 1995
  ident: 10.1016/j.carres.2024.109195_bib12
  article-title: Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex
  publication-title: Mol. Med.
  doi: 10.1007/BF03401604
– volume: 54
  start-page: 4462
  year: 2015
  ident: 10.1016/j.carres.2024.109195_bib34
  article-title: Thermodynamic switch in binding of adhesion/growth regulatory human galectin-3 to tumor-associated TF antigen (CD176) and MUC1 glycopeptides
  publication-title: Biochemistry
  doi: 10.1021/acs.biochem.5b00555
– volume: 31
  start-page: 129
  year: 2017
  ident: 10.1016/j.carres.2024.109195_bib11
  article-title: Preliminary mass spectrometry characterization studies of galectin‐3 samples, prior to carbohydrate‐binding studies using Affinity mass spectrometry
  publication-title: Rapid Commun. Mass Spectrom.
  doi: 10.1002/rcm.7775
SSID ssj0000676
Score 2.4380863
Snippet Non-enzymatic cascade reactions between amines and reducing sugars are known as Maillard reaction. The late phase of these reactions consists of advanced...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 109195
SubjectTerms AlphaScreen
Amadori compounds
amino acid sequences
Blood Proteins
enkephalin
Enkephalin, Leucine - chemistry
Enkephalin, Leucine - metabolism
Enkephalins - chemistry
Enkephalins - metabolism
Galectin 3 - chemistry
Galectin 3 - metabolism
Galectin-3
galectins
Galectins - chemistry
Galectins - metabolism
Heyns compounds
Humans
Leu-enkephalin
Ligands
Maillard reaction
moieties
pathogenesis
Peptides - chemistry
Protein Binding
sugars
Title Amadori and Heyns rearrangement products of bioactive peptides as potential new ligands of galectin-3
URI https://dx.doi.org/10.1016/j.carres.2024.109195
https://www.ncbi.nlm.nih.gov/pubmed/38908217
https://www.proquest.com/docview/3071283311
https://www.proquest.com/docview/3153664907
Volume 542
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NS8NAEF1ED3oRv61frOB1tWm2SXMsRakWPYiit2WT7EpEk9DUgxd_u_OyiSj4AZ5Ky4Qss5t5j_TNG8aOUnqAIl8bIcMkFHCYE4MBZGLWRjogPIpqx5vLq2B8Ky_u-_dzbNT2wkBW2dR-V9Prat38ctJk86TMMvT4go4T_kiUWolGcylDnPLjN-9zNQ4cBR4IRLftc7XGK4EcFqbdPQlfJQ9TJr6Hp5_oZw1DZytsueGPfOiWuMrmTL7GFkft2LZ1ZobPOi2mGdd5ysfmNa_4FHpcNBHgTSAvncdrxQvL46zQdcHjJdQtqam4rnhZzKAhotsQ5-ZP2QPagREONKHwXPgb7Pbs9GY0Fs0sBZH4UX8mrB_CeAbm-ZooWI-YiSVyAr-vbkoPsQnlwCZp2of7T2zg8xVgHllkegYcyt9k83mRm23Gte3plFhVTExIStsnxuvZiJAuNt0o8ZIO89sUqqQxGse8iyfVKsoelUu8QuKVS3yHiY-rSme08Ud82O6O-nJgFGHBH1cetpupaG_wB4nOTfFSKap3BNe-73m_xBBEBIGMumGHbbmT8LFeShcxKi_c-ffadtkSvjmF4R6bn01fzD6xnll8UB_rA7YwPJ-Mr_A5ub6bvAOvTgAV
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT4NAEJ5oe6gX49v6XBOvG0tZoBybRoOP9qRJb5sFdg1GgZR68N87w4LRxEfiFXbDZnaZ7wt88w3AeYovUOgqzUWQBJwc5vhoRDIxY0LlIx6FtePNdOZHD-Jm7s1XYNLWwpCsssn9NqfX2bq5ctFE86LMMqrxJTqO-CMo1QpvFbrkTuV1oDu-vo1mnxOyb1nwiNOEtoKulnklpIgl3-6hIGslhxpNfI9QPzHQGomuNmC9oZBsbFe5CSs634LepO3ctg16_KLSYpExlacs0m95xRYkyaU6AvoYyEpr81qxwrA4K1Sd81hJApdUV0xVrCyWJCPCxyDtZs_ZI1UE03ACFByec3cHHq4u7ycRb9op8MQNvSU3bkDeM-Sfr5CFDZGcGOQnZPk1SPE91oEYmSRNPTIAijVZffnUkizUQ000yt2FTl7keh-YMkOVIrGKkQwJYTwkvY4JEexiPQgTJ-mD24ZQJo3XOLW8eJatqOxJ2sBLCry0ge8D_5hVWq-NP8YH7e7IL2dGIhz8MfOs3UyJe0P_SFSui9dKYspDxHZdx_llDKKE74twEPRhz56Ej_ViuJBUOcHBv9d2Cr3ofnon765nt4ewRnes4PAIOsvFqz5GErSMT5pD_g5t3AEj
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Amadori+and+Heyns+rearrangement+products+of+bioactive+peptides+as+potential+new+ligands+of+galectin-3&rft.jtitle=Carbohydrate+research&rft.au=Jakas%2C+Andreja&rft.au=Ayyalasomayajula%2C+Ramya&rft.au=Cudic%2C+Mare&rft.date=2024-08-01&rft.issn=0008-6215&rft_id=info:doi/10.1016%2Fj.carres.2024.109195&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-6215&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-6215&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-6215&client=summon